“SPR Evaluation of Potential Anti-COVID-19 Therapies” poster presentation at ELRIG Drug Discovery Digital 2020
ELRIG Drug Discovery Digital 2020 is starting this week, and Dr Clare Box and Dr Kevin Thompson are going to be there, virtually, to present their research evaluating novel COVID-19 therapies through the use of SPR. ELRIG Drug Discovery DigitalfacebooktwitterCopyright...
Small Molecules, Binding to AT2 Site on ACE2, Unlikely to Prevent COVID-19 Spike Protein Binding
Angiotensin II and SARS-CoV-2 ‘spike’ protein bind to independent sites on angiotensin converting enzyme 2. We used the Biacore Surface Plasmon Resonance (SPR) technique to show that the peptide angiotensin II (AT2, that is normally truncated by the ACE2 receptor) and...
COVID-19 Decoy: ACE2 in Solution “Decoys” Spike Protein, Inhibiting Binding to Surface Bound ACE2
Using the Biacore Surface Plasmon Resonance (SPR) technique, we have quantified the kinetic receptor binding parameters for COVID-19 / SARS-CoV-2 ‘spike’ protein to the trans-membrane receptor Angiotensin Converting Enzyme 2 (ACE2). Notably, when ACE2 is pre-mixed...
Coronavirus and Business Continuity
Gifford Bioscience is currently operational, prioritising COVID-19 work on the SARS-CoV2 spike protein : ACE2 interaction, using both SPR Biacore and radiometric techniques. The studies are with recombinant protein, live cells and human lung and brain...
